Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis
BackgroundOne of the most significant risk factors for relapse and hospitalization in schizophrenia is non-adherence to antipsychotic medications, very common in patients with schizophrenia. The aim of this analysis was to evaluate the treatment persistence to aripiprazole once-monthly (AOM) and the...
Main Authors: | José Manuel Olivares, Andrea Fagiolini |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-04-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2022.877867/full |
Similar Items
-
Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies
by: Daniel Schöttle, et al.
Published: (2022-01-01) -
Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study
by: José Manuel Olivares, et al.
Published: (2021-01-01) -
Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen
by: S.L. Romero Guillena, et al.
Published: (2022-06-01) -
Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study – CORRIGENDUM
by: José Manuel Olivares, et al.
Published: (2021-01-01) -
Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
by: Oloruntoba Oluboka, et al.
Published: (2023-05-01)